Skip to content
ADVERTISEMENT
Sign In
  • Sections
    • News
    • Advice
    • The Review
  • Topics
    • Data
    • Diversity, Equity, & Inclusion
    • Finance & Operations
    • International
    • Leadership & Governance
    • Teaching & Learning
    • Scholarship & Research
    • Student Success
    • Technology
    • Transitions
    • The Workplace
  • Magazine
    • Current Issue
    • Special Issues
    • Podcast: College Matters from The Chronicle
  • Newsletters
  • Events
    • Virtual Events
    • Chronicle On-The-Road
    • Professional Development
  • Ask Chron
  • Store
    • Featured Products
    • Reports
    • Data
    • Collections
    • Back Issues
  • Jobs
    • Find a Job
    • Post a Job
    • Professional Development
    • Career Resources
    • Virtual Career Fair
  • More
  • Sections
    • News
    • Advice
    • The Review
  • Topics
    • Data
    • Diversity, Equity, & Inclusion
    • Finance & Operations
    • International
    • Leadership & Governance
    • Teaching & Learning
    • Scholarship & Research
    • Student Success
    • Technology
    • Transitions
    • The Workplace
  • Magazine
    • Current Issue
    • Special Issues
    • Podcast: College Matters from The Chronicle
  • Newsletters
  • Events
    • Virtual Events
    • Chronicle On-The-Road
    • Professional Development
  • Ask Chron
  • Store
    • Featured Products
    • Reports
    • Data
    • Collections
    • Back Issues
  • Jobs
    • Find a Job
    • Post a Job
    • Professional Development
    • Career Resources
    • Virtual Career Fair
    Upcoming Events:
    College Advising
    Serving Higher Ed
    Chronicle Festival 2025
Sign In
Brainstorm Logo-Icon

Brainstorm

Ideas and culture.

Send Lawyers, Guns, and Stem Cells

By Carl Elliott March 1, 2012

Just over a decade ago, a new financial opportunity appeared in the field of bioethics. Pharmaceutical and biotechnology companies were

To continue reading for FREE, please sign in.

Sign In

Or subscribe now to read with unlimited access for as low as $10/month.

Don’t have an account? Sign up now.

A free account provides you access to a limited number of free articles each month, plus newsletters, job postings, salary data, and exclusive store discounts.

Sign Up

Just over a decade ago, a new financial opportunity appeared in the field of bioethics. Pharmaceutical and biotechnology companies were giving away money. Some companies had started making contributions to bioethics centers; others paid bioethicists to work as consultants and advisers; still others funded endowed chairs and branded awards.

Many bioethicists welcomed the money, arguing that it would support the good work being done by the field; others thought that it might present a conflict of interest, but one that was manageable as long as the source of the money was disclosed. My own reaction was slightly different. To me, the pharmaceutical industry was the serpent in the garden, and its head would need to be crushed.

It was at this point that I began to deliver what some people call my “sinners in the hands of an angry god” sermons. Apparently, I thought that if I just produced a sufficient number of articles and lectures condemning the pharmaceutical industry, the bioethicists who were eagerly accepting industry money would feel so ashamed that they would repent and sin no more. Unsurprisingly, things didn’t really work out that way. My altar calls never really got much of a response. Most of the congregation just sat quietly in their pews, waiting patiently for the benediction, while the sinners got more resolute in their sins.

ADVERTISEMENT

Of course, there have been many occasions to reconsider the wisdom of my strategy. My sermons have prompted their share of angry condemnations, not to mention a handful of trolls who stalk me on the Internet, posting insults whenever I publish an article. (Some of the insults are actually pretty funny.) A piece I wrote for Mother Jones about a suicide in a pharmaceutical research study at the University of Minnesota has put me at odds with the administration and the general counsel’s office at my own university.

But I had never actually been threatened with legal action until this week, when I got a letter from a lawyer representing Glenn McGee, the former editor of the American Journal of Bioethics. Since December McGee has been working as “President for Ethics and Strategic Initiatives” for a Texas stem cell clinic called Celltex, whose questionable activities and those of its South Korean partner, RNL Bio, have been detailed in a series of recent articles in Nature. (You can see some of the articles here, here, and here.) The problem presented by a bioethics journal editor working full-time for a dubious stem-cell company has prompted a lot of spirited commentary in the field, and two weeks ago, I wrote about McGee’s relationship with Celltex and its controversial partner, RNL Bio, for Slate. That article prompted a demand for retraction by McGee, accompanied by the threat of legal action.

To me, the threat seemed absurd, especially given the nature of McGee’s complaints. Of course, I offered to correct any factual errors in the piece; that would be only fair. And there did seem to be a couple of errors. But to my astonishment, the Slate editors took the threat very seriously, and decided to retract the article over my objections. (Slate editors will be making an appearance in my sermons now.) In any case, just as Slate was retracting my article, McGee was announcing his resignation from Celltex, presumably in response to the alarming articles in Nature detailing exactly what Celltex has been doing. (A key sentence in the Nature editorial: “The U.S. Food and Drug Administration (FDA) considers it to be a crime to inject unapproved adult stem cells into patients.”) As for my now-dead Slate article: well, I have sent a copy of McGee’s demands to Bill Heisel at Reporting on Health, as well as my responses to his allegations. Heisel has posted them here, along with his take on the whole affair. You can see for yourself whether it warranted a retraction. Personally, I am looking forward to a resurrection of the article, perhaps in another form.

We welcome your thoughts and questions about this article. Please email the editors or submit a letter for publication.
Share
  • Twitter
  • LinkedIn
  • Facebook
  • Email
ADVERTISEMENT
ADVERTISEMENT

More News

Vector illustration of large open scissors  with several workers in seats dangling by white lines
Iced Out
Duke Administrators Accused of Bypassing Shared-Governance Process in Offering Buyouts
Illustration showing money being funnelled into the top of a microscope.
'A New Era'
Higher-Ed Associations Pitch an Alternative to Trump’s Cap on Research Funding
Illustration showing classical columns of various heights, each turning into a stack of coins
Endowment funds
The Nation’s Wealthiest Small Colleges Just Won a Big Tax Exemption
WASHINGTON, DISTICT OF COLUMBIA, UNITED STATES - 2025/04/14: A Pro-Palestinian demonstrator holding a sign with Release Mahmud Khalil written on it, stands in front of the ICE building while joining in a protest. Pro-Palestinian demonstrators rally in front of the ICE building, demanding freedom for Mahmoud Khalil and all those targeted for speaking out against genocide in Palestine. Protesters demand an end to U.S. complicity and solidarity with the resistance in Gaza. (Photo by Probal Rashid/LightRocket via Getty Images)
Campus Activism
An Anonymous Group’s List of Purported Critics of Israel Helped Steer a U.S. Crackdown on Student Activists

From The Review

John T. Scopes as he stood before the judges stand and was sentenced, July 2025.
The Review | Essay
100 Years Ago, the Scopes Monkey Trial Discovered Academic Freedom
By John K. Wilson
Vector illustration of a suited man with a pair of scissors for a tie and an American flag button on his lapel.
The Review | Opinion
A Damaging Endowment Tax Crosses the Finish Line
By Phillip Levine
University of Virginia President Jim Ryan keeps his emotions in check during a news conference, Monday, Nov. 14, 2022 in Charlottesville. Va. Authorities say three people have been killed and two others were wounded in a shooting at the University of Virginia and a student is in custody. (AP Photo/Steve Helber)
The Review | Opinion
Jim Ryan’s Resignation Is a Warning
By Robert Zaretsky

Upcoming Events

07-31-Turbulent-Workday_assets v2_Plain.png
Keeping Your Institution Moving Forward in Turbulent Times
Ascendium_Housing_Plain.png
What It Really Takes to Serve Students’ Basic Needs: Housing
Lead With Insight
  • Explore Content
    • Latest News
    • Newsletters
    • Letters
    • Free Reports and Guides
    • Professional Development
    • Events
    • Chronicle Store
    • Chronicle Intelligence
    • Jobs in Higher Education
    • Post a Job
  • Know The Chronicle
    • About Us
    • Vision, Mission, Values
    • DEI at The Chronicle
    • Write for Us
    • Work at The Chronicle
    • Our Reporting Process
    • Advertise With Us
    • Brand Studio
    • Accessibility Statement
  • Account and Access
    • Manage Your Account
    • Manage Newsletters
    • Individual Subscriptions
    • Group and Institutional Access
    • Subscription & Account FAQ
  • Get Support
    • Contact Us
    • Reprints & Permissions
    • User Agreement
    • Terms and Conditions
    • Privacy Policy
    • California Privacy Policy
    • Do Not Sell My Personal Information
1255 23rd Street, N.W. Washington, D.C. 20037
© 2025 The Chronicle of Higher Education
The Chronicle of Higher Education is academe’s most trusted resource for independent journalism, career development, and forward-looking intelligence. Our readers lead, teach, learn, and innovate with insights from The Chronicle.
Follow Us
  • twitter
  • instagram
  • youtube
  • facebook
  • linkedin